Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Leukemias or Myelodysplastic Syndrome (MDS)
Conditions
Interventions
fadraciclib
Locations
2
United States
City of Hope
Duarte, California, United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
October 22, 2021
Primary Completion Date
October 1, 2024
Completion Date
December 1, 2024
Last Updated
February 8, 2024
NCT05564390
NCT07320235
NCT06846671
NCT06514534
NCT07218341
NCT05475925
Lead Sponsor
Cyclacel Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions